Introduction
The release of neurotransmitters from neural and neuroendocrine cells is mediated by the exocytotic fusion of synaptic vesicles and dense-core vesicles (DCVs) with the plasma membrane in a process activated by cytoplasmic Ca 2 ϩ elevations (Rettig and Neher, 2002) . Secretory vesicles dock at the plasma membrane and undergo priming, which confers competence for Ca 2 ϩ -triggered fusion (Robinson and Martin, 1998) . Identification of phosphatidylinositol transfer protein and the phosphatidylinositol 4-phosphate 5-kinase type I (PIP5KI) as factors required for ATP-dependent priming indicated that phosphatidylinositol 4,5-bisphosphate (PIP 2 ) is essential for the Ca 2 ϩ -dependent exocytosis of docked DCVs (Eberhard et al., 1990; Hay and Martin, 1993; Hay et al., 1995) . A type II PI 4-kinase on DCVs (Wiedemann et al., 1996; Barylko et al., 2001 ) and a cytosolic or plasma membrane type I PIP5K (Hay et al., 1995; Wenk et al., 2001) have been implicated in the synthesis of plasma membrane PIP 2 (Holz et al., 2000) required for DCV exocytosis.
Plasma membrane PIP 2 is also essential for mediating the sequential recruitment of adaptor and accessory proteins to sites of clathrin-dependent endocytosis (Cremona and DeCamilli, 2001) . The requirement for PIP 2 as a cofactor for both endocytosis and exocytosis suggests that its synthesis at localized sites of fission and fusion is tightly regulated, but little is known about the control of PIP 2 synthesis. Recent analyses identified protein kinases and phosphatases that regulate the type I PIP5K (Park et al., 2001 ). An important advance was the finding that ADPribosylation factor (ARF) GTPases directly activate type I PIP5K enzymes (Honda et al., 1999; Jones et al., 2000) .
The ARF proteins are GTPases that function as regulators of membrane traffic (Randazzo et al., 2000) . ARF6, the sole member of the class III ARF family, resides on endosomes and the plasma membrane and regulates membrane traffic between these compartments (D'Souza-Schorey et al., 1995; Peters et al., 1995) . ARF6 functions as a switch that cycles through GTP for GDP exchange and GTP hydrolysis. Correspondingly, studies of its function have used expression of dominant-negative GTP-binding deficient mutants (e.g., ARF6
T27N ) or of constitutively active GTPase-deficient mutants (e.g., ARF6 Q67L ) to perturb membrane trafficking. Activation of ARF6 promotes peripheral actin assembly (Schafer et al., 2000) , plasma membrane protrusions and invaginations (Peters et al., 1995; D'Souza-Schorey et al., 1998) , pinocytosis (Brown et al., 2001) , and the internalization of plasma membrane proteins via clathrin-dependent (D' Souza-Schorey et al., 1995; Altschuler et al., 1999; Claing et al., 2001; Palacios et al., 2002) or clathrin-independent (Radhakrishna et al., 1996; Radhakrishna and Donaldson, 1997; Brown et al., 2001; Delaney et al., 2002) endocytosis.
Unlike the results in other cell types, ARF6 was reported to localize to DCVs in adrenal chromaffin cells and to undergo translocation from DCVs to the plasma membrane in response to the stimulation of exocytosis (Galas et al., 1997; Caumont et al., 1998) . Whether ARF6 plays a direct role in regulated DCV exocytosis or exerts indirect effects through cytoskeletal rearrangements or plasma membrane-endosomal trafficking remains to be determined. We found that ARF6 localizes to the plasma membrane and recycling endosomes, but not to DCVs in neuroendocrine PC12 cells. Cells expressing the GTPase-deficient ARF6 Q67L mutant exhibited reduced rates of Ca 2 ϩ -triggered DCV exocytosis resulting from the diversion of plasma membrane PIP 2 and PIP5K to endosomal membranes. The restoration of DCV exocytosis by addition of PIP5K to permeable cells required Ca 2 ϩ , which activated PIP5K and increased its association with ARF6. These results indicate that ARF6 plays a role in DCV exocytosis by controlling the activity of PIP5K and the synthesis of a required plasma membrane pool of PIP 2 . tant ARF6 proteins (GTPase-deficient ARF Q67L or GTP binding-deficient ARF6 T27N ) were expressed in PC12 cells (Fig. 1 B) . Human growth hormone (hGH), which is stored in DCVs, was coexpressed to enable the detection of regulated secretion in the transfected cells (Zhang et al., 2002) . Ca 2 ϩ -dependent hGH secretion was elicited in brief incubations in high K ϩ -containing buffer to promote Ca 2 ϩ influx, and was compared with basal secretion in Na ϩ -containing buffer. Expression of wild-type and GTP binding-deficient ARF6 T27N did not affect the basal release of hGH, but expression of the GTPase-deficient ARF6 Q67L increased basal release approximately twofold (Fig. 1 A, open bars) , which may correspond to the Ca 2 ϩ -independent, GTP-dependent stimulation of DCV exocytosis characterized in permeable PC12 cells (Banerjee et al., 1996) . Ca 2 ϩ influx-dependent hGH secretion stimulated by K ϩ depolarization was unaffected by expression of either wild-type or ARF6
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T27N , but was consistently inhibited in ARF6 Q67L -expressing cells ( Fig. 1 A, Q67L , respectively). Because ARF6 Q67L , reported to alter peripheral membrane trafficking in other cell types, affected DCV exocytosis in PC12 cells, subsequent analyses were undertaken to determine the basis for the inhibition.
Expression of wild-type or either of the ARF6 mutants did not affect the cellular distribution of hGH ( Fig. 1 C, right panels) in the Golgi or in DCVs, indicating that the synthesis and transport of hGH through the secretory pathway were unaffected by ARF6 expression. The wild-type and ARF Q67L expressed proteins localized to the plasma membrane and to cytoplasmic vesicular membranes, whereas the ARF6 T27N protein was predominantly localized to cytoplasmic vesicular membranes ( Fig. 1 C, left panels) , as reported for other cell types (D'Souza-Schorey et al., 1995; Peters et al., 1995) . ARF6-containing cytoplasmic vesicles ( Fig. 1 C, arrows) were readily distinguished from hGH-immunoreactive DCVs. Neither docked DCVs containing hGH ( Fig. 1 C, arrowheads) nor cytoplasmic DCVs (Fig. 1 C, insets) colocalized with ARF6-containing cytoplasmic vesicles. Endogenous ARF6 was weakly detected in cytoplasmic vesicular membranes and on the plasma membrane ( Fig. 1 C) , and this localization was clearly distinct from that of chromogranin B, an endogenous DCV constituent (Fig. 1 C) . Overall, these results indicated that ARF6 proteins are not present on DCVs, and that the inhibition of Ca 2 ϩ -dependent DCV exocytosis by ARF6 Q67L was unlikely the result of either an altered DCV localization or of a direct effect of ARF6 on DCVs.
ARF6 colocalizes with transferrin-and Rab11-positive endosomes in PC12 cells
In other cell types, ARF6 is present in endosomal compartments and on the plasma membrane (D'Souza-Schorey et al., 1995; Peters et al., 1995; Radhakrishna and Donaldson, 1997) . Although ARF6 was reported to be present on DCVs in chromaffin cells (Galas et al., 1997; Caumont et al., 1998) , this was not the case for neuroendocrine PC12 cells (Fig. 1 C) . To identify the cytoplasmic vesicles containing ARF6, colocalization studies were conducted for proteins characteristic of secretory and endocytic compartments. Cytoplasmic ARF6 (Fig. 2 A, arrows) did not colocalize with either TGN38 or with mannosidase II. ARF6-containing vesicles were more diffusely localized around the perinuclear region after treatment with brefeldin A (BFA; Fig. 2 A) , which causes tubulation of endosomes, the TGN, and lysosomes (Lippincott-Schwartz et al., 1991) . BFA treatment also affected mannosidase II-containing and TGN38-containing Golgi elements (Fig. 2 A) , as well as transferrin-positive endosomal compartments (unpublished data). The distributions of wild-type and ARF6 Q67L (unpublished data) and endocytosed transferrin, a marker for recycling endosomes, overlapped extensively, but not precisely (Fig. 2 B, inset) , indicating that cytoplasmic ARF6 proteins were localized to a subdomain of recycling endosomes. Consistent with this, ARF6-containing membranes colocalized extensively with Rab11-positive late endosomes (Fig. 2 B, arrows) . The localization of ARF Q67L at the plasma membrane and in recycling endosomes suggested that the ARF6 Q67L inhibition of DCV exocytosis was indirect and caused by alterations in endosomal plasma membrane trafficking.
Recruitment of PIP5K by ARF6
Q67L alters the cellular distribution of PIP 2 In other cell types, the expression of the GTPase-deficient ARF6
Q67L induces an accumulation of endosomal membranes leading to the intracellular trapping of plasma membrane constituents that normally recycle (Brown et al., 2001; Naslavsky et al., 2003) . We considered the possibility that a plasma membrane constituent essential for regulated DCV exocytosis was depleted from the plasma membrane in cells expressing ARF6 Q67L . Indeed, SNAP-25, a plasma membrane SNARE required for DCV exocytosis (Banerjee et al., 1996) , was found to substantially relocalize to an endosomal compartment in ARF6 Q67L -expressing cells (unpublished data); however, we were unable to rescue regulated hGH release by overexpressing SNAP-25. Another plasma membrane constituent required for DCV exocytosis is PIP 2 (Hay et al., 1995) , and we found that plasma membrane pools of PIP 2 were dramatically altered by ARF6 Q67L expression. A PLC ␦1 pleckstrin homology (PH) domain-GFP fusion protein was expressed to detect membraneassociated PIP 2 as described previously (Varnai and Balla, 1998) . PC12 cells expressing high levels of wild-type ARF6 exhibited a uniform distribution of the PH-GFP at the plasma membrane (Fig. 3 A) , which colocalized with plasma membrane ARF6. In contrast, cells expressing ARF6 Q67L exhibited a very different distribution of the PH-GFP protein. At low expression levels, the PH-GFP localized to the plasma membrane as well as to intracellular endosomal membranes that contained ARF6 Q67L (Fig. 3 A) . Cells expressing higher levels of ARF6 Q67L , representing ‫%52ف‬ of the cell population, accumulated intracellular inclusions enriched in the PH-GFP protein as well as ARF6 Q67L ( Fig. 3 A, arrow). Plasma membrane-associated PH-GFP was markedly decreased in these cells (Fig. 3 A, insets), and the cells resembled ARF6 Q67L -expressing fibroblasts in which PIP 2 -positive vacuoles accumulated (Brown et al., 2001 ). This feature was unique for ARF6 Q67L expression and was not observed for ARF6
WT or ARF6 T27N (Fig. 3  A) . Quantitation of digital images documented that the PH-domain of PLC␦1 was depleted from the plasma membrane ( Fig. 3 B, left) and preferentially accumulated on endosomal membranes (Fig. 3 A shift of the PH-GFP protein from plasma membrane to endosomes in ARF6 Q67L -expressing cells implied that the distribution of PIP 2 was markedly altered. To confirm this directly, we determined the plasma membrane content of PIP 2 in permeable cells using a PIP 2 antibody that revealed a punctate staining pattern ( Fig. 3 C, red channel). The PIP 2 content of the plasma membrane was not altered in cells expressing ARF6
WT or ARF6 T27N ( Fig. 3 C) , but was strongly decreased in cells expressing ARF6 Q67L (Fig. 3 C, arrows). Quantitation of digital images documented a highly significant decrease for plasma membrane PIP 2 in cells expressing ARF6 Q67L (Fig. 3 D) . Overall, the results indicated that ARF6 Q67L expression promotes a redistribution of PIP 2 in PC12 cells from the plasma membrane to an intracellular endosomal compartment.
The preferential accumulation of PIP 2 in an endosomal compartment might result from either the translocation of plasma membrane containing PIP 2 or the redirected synthesis of PIP 2 on endosomes. ARF proteins directly regulate PIP5K activity (Honda et al., 1999; Jones et al., 2000) , and the constitutively active ARF6 Q67L localized to endosomes may persistently activate PIP5K on endosomal membranes. To examine this possibility directly, we coexpressed HAtagged PIP5KI␥ with ARF6-GFP and determined their distribution (Fig. 4) . PIP5KI␥ preferentially localized to the plasma membrane in cells expressing wild-type ARF6 or low levels of ARF6 Q67L where there was extensive colocalization of PIP5KI␥ with the ARF6 proteins (Fig. 4) . Cells expressing higher levels of ARF6 Q67L exhibited a striking redistribution of PIP5KI␥ to intracellular membranes where the enzyme colocalized with the ARF6 protein (Fig. 4, arrow) . Plasma membrane PIP5KI␥ was substantially decreased in these cells (Fig. 4, insets) , indicating that ARF6 Q67L diverts PIP5K to endosomal membranes. This redistribution of PIP5K would account for the accumulation of PIP 2 in an endosomal compartment (Fig. 3 A, arrow) . The results indicated that the GTPase-deficient ARF6 Q67L induces a shift in the distribution of PIP5K and PIP 2 from the plasma membrane to intracellular membranes.
Restoration of Ca
2ϩ -dependent exocytosis by PIP5K by a Ca 2ϩ -dependent mechanism To further probe the mechanism by which ARF6 Q67L inhibited Ca 2ϩ -dependent DCV exocytosis, we determined whether inhibition was preserved in permeable PC12 cells where DCV exocytosis can be directly triggered by Ca 2ϩ addition (Hay and Martin, 1992) . Expression of ARF6 Q67L (but not wild-type ARF6 or ARF6 T27N ) resulted in the inhibition of Ca 2ϩ -triggered hGH release by ‫%84ف‬ in permeable cells (Fig. 5 A, middle bars) , which corresponded closely to the intact cell assay results (Fig. 1 A) . However, when MgATP and rat brain cytosol were included in the incubations to fully reconstitute Ca 2ϩ -dependent exocytosis, the inhibitory effect of ARF6 Q67L was not observed ( To determine whether MgATP and cytosol were sufficient for reversing the inhibitory effects of ARF6 Q67L , a two-stage assay was used. MgATP-and cytosol-dependent priming reactions were conducted before Ca 2ϩ -triggering incubations, which contained Ca 2ϩ and cytosol, but not MgATP (Hay and Martin, 1992) . We found that the inhibition by ARF6 Q67L was preserved in the two-stage assay over the entire time course of Ca 2ϩ -evoked hGH release (Fig. 5 B) . Together with the other findings, this result indicates that all three constituents, MgATP, cytosol, and Ca 2ϩ , but no two of these alone, were essential for restoring regulated DCV exocytosis in ARF6 Q67L -expressing cells. Because the reversal of ARF6 Q67L inhibition was dependent on MgATP and cytosol in permeable cells in which plasma membrane PIP 2 and PIP5K had been depleted, it was very likely that the soluble PIP5K enzymes present in cytosol were responsible for the restoration of DCV exocytosis. To test the role of PIP5K directly, we attempted to rescue the inhibitory effect of ARF6 Q67L by expressing the type I␥ PIP5K. Expression of PIP5KI␥ successfully counteracted the inhibitory effect of ARF6 Q67L on Ca 2ϩ -activated hGH release in permeable cells (Fig. 6 A) . As anticipated, rescue by PIP5KI␥ was only evident in incubations that included MgATP and failed to occur with expression of a kinase-dead truncation mutant of PIP5KI␥ ⌬345 (Fig. 6 A) , which did not localize to the plasma membrane (unpublished data). In addition, the reversal of ARF6 Q67L inhibition by expression of the wild-type PIP5KI␥ enzyme did not require addition of cytosol (Fig. 6 A) . These results indicate that reversal of ARF6 Q67L inhibition can be achieved by PIP5KI␥ overexpression, and they imply that the factor in cytosol required for the reversal is one of the abundant cytosolic PIP5K enzymes (Hay et al., 1995; Wenk et al., 2001) . Indeed, direct addition of a pure recombinant PIP5KI␥ protein to the permeable cell assay was effective in counteracting the inhibitory effects of ARF6 Q67L (Fig. 6 B) . Multiple isoforms of PIP5K have been characterized consisting of types I␣, I␤, and I␥ (Ishihara et al., 1998; Anderson et al., 1999) . We found that expression of the type I␣ (human) PIP5K also reversed the ARF6 Q67L inhibition, whereas the kinase-dead (D309N/R427Q) PIP5KI␣ failed to provide rescue (Fig. 6 C) . Both active and inactive enzymes were equally well expressed and associated with the plasma membrane (Fig. 6 D) . Expression of the type I␤ (human) PIP5K provided only weak rescue, but was poorly expressed (unpublished data). Overall, the results strongly support the conclusion that the depletion of PIP 2 from the plasma membrane induced by long-term expression of ARF6 Q67L was responsible for the inhibition of regulated DCV exocytosis.
PIP5KI␥ is regulated by phosphorylationand ARF6-dependent mechanisms
These results on PIP5K provided an explanation for why MgATP and cytosol counteracted the inhibition of exocytosis mediated by ARF6 Q67L expression, but they did not account for the additional requirement for Ca 2ϩ in the rescue. Thus, we determined whether a requirement for Ca 2ϩ in the restoration was related to the regulation of PIP5K activity. The phosphorylation of Ser214 in mouse PIP5KI␣ was reported to decrease lipid kinase activity, whereas PKC was reported to stimulate lipid kinase activity by promoting protein phosphatase-mediated dephosphorylation of the enzyme (Park et al., 2001) . Thus, the requirement of Ca 2ϩ , in addition to MgATP and cytosol, for counteracting ARF6 Q67L inhibition might be mediated by the Ca 2ϩ -dependent activation of PKC, which may enhance PIP5K activity. Consistent with this, we found that the specific pseudosubstrate inhibitor of PKC fully blocked the reversal of ARF6 Q67L inhibition observed with Ca 2ϩ , MgATP, and cytosol in permeable cell incubations (Fig. 7 A) .
To determine the role of dephosphorylation in the regulation of PIP5K activity, we constructed the cognate nonphos- phorylatable S264A mutant of PIP5KI␥, which was anticipated to be active relative to the wild-type enzyme. Both wild-type and S264A PIPKI␥ were expressed at similar levels in transfected PC12 cells, and each localized to the plasma membrane (Fig. 7 D, left panels) . Expression of the S264A PIP5KI␥ mutant enhanced Ca 2ϩ -dependent hGH secretion by ‫%03ف‬ (Fig. 7 B) , whereas expression of wild-type PIP5KI␥ had little effect, consistent with the possible constitutive activity of the S264A PIPKI␥ enzyme. Indeed, cells expressing the S264A mutant PIPKI␥ exhibited substantially greater increases in plasma membrane PIP 2 than those expressing the wild-type enzyme ( Fig. 7 C and Fig. 7 Da, right). Quantitation of plasma membrane immunoreactive PIP 2 (Fig. 7 Db) indicated that Ͼ32% of S264A PIP5KI␥-expressing cells exceeded threshold values of immunoreactive PIP 2 , compared with Ͻ10% of wild-type PIPKI␥-expressing cells. Overall, the results indicate that phosphorylation at Ser264 may control the activity of PIP5KI␥ and that plasma membrane PIP 2 levels regulate Ca 2ϩ -dependent exocytosis. ARF proteins were reported to directly activate purified type I␣ (mouse) PIP5K (Honda et al., 1999; Jones et al., 2000) and ARF6 was shown to be recruited with PIP5K I␣ to plasma membrane sites in fibroblasts (Honda et al., 1999) , but a direct interaction of ARF6 with PIP5K has not been demonstrated. To determine whether ARF6 associates with PIP5K, coimmunoprecipitation experiments were conducted (Fig. 8 A) . ARF6 was found to co-immunoisolate with PIP5KI␥ in resting cells, and this was enhanced by Ca 2ϩ influx stimulated by K ϩ depolarization (Fig. 8 A, a and  b) . ARF6 Q67L and ARF6 N122I proteins exhibited similar associations with PIP5KI␥ that were enhanced by Ca 2ϩ influx (Fig. 8 Ba) . The results indicate that the association of ARF6 with PIP5K is regulated by a Ca 2ϩ -dependent mechanism. To determine if this Ca 2ϩ -dependent mechanism involves PIP5K dephosphorylation, immunoprecipitations were conducted with cells expressing the nonphosphorylatable S264A PIP5KI␥ mutant. ARF6 exhibited substantial association with the S264A enzyme in resting cells, and this was not further enhanced by K ϩ depolarization and Ca 2ϩ influx (Fig. 8  A, a and b) . ARF6 Q67L and ARF6 N122I proteins exhibited a similar association with the S264A PIP5KI␥ that was not enhanced by Ca 2ϩ influx (Fig. 8 Bb) . The results indicate that, in addition to enhancing PIP5K activity, Ca 2ϩ increases the association of PIP5K with ARF6. Interactions between ARF6 and PIP5K appear to be governed principally by the phosphorylation state of PIP5K rather than the guanine nucleotide-bound state of ARF6. The association of PIP5K with membrane-bound ARF6 may be important for targeting the enzyme to its membrane PI(4)P substrate. Overall, the results suggest a pathway by which Ca 2ϩ enhances PIP 2 synthesis for DCV exocytosis via an ARF6-dependent PIP5K (Fig. 9) .
Discussion
Basis of the inhibition of DCV exocytosis by ARF6
Q67L expression In this work, we sought to characterize the role of ARF6 in the mechanisms that regulate Ca 2ϩ -dependent DCV exocytosis in neuroendocrine PC12 cells. Expression of the constitutively active GTPase-deficient ARF6 Q67L mutant exerted a strong inhibitory effect on regulated DCV exocytosis. Subsequent analyses clarified the nature of the inhibitory effect as consisting of a diversion of plasma membrane constituents that are required for DCV exocytosis, PIP5K, and PIP 2 , to endosomal membranes with their corresponding depletion from the plasma membrane.
As reported for other cell types (D'Souza-Schorey et al., 1995; Peters et al., 1995) , the distribution of ARF6 proteins in PC12 cells was restricted to the plasma membrane and endosomal membranes. The restricted localization of ARF6 to these compartments in PC12 cells was unanticipated in view of the reported biochemical localization of ARF6 to the DCVs of chromaffin cells (Galas et al., 1997; Caumont et al., 1998) . However, the degree of purity of DCVs was not assessed in those experiments, and immunocytochemical localization analyses were not reported. Vitale et al. (2002) reported immunocytochemical experiments in PC12 cells indicating that ARF6 proteins colocalize with DCV markers. However, there was a broad cytoplasmic distribution of both ARF6 and DCV markers by fluorescence microscopy that would preclude resolution of the clearly distinct distributions that we observed (Fig. 1 C) . Moreover, an immunogold electron microscopic analysis (Vitale et al., 2002) was consistent with the localization of ARF6 proteins to cytoplasmic membranes other than DCVs. In other cell types, ARF6 traffics between endosomal and plasma membrane compartments and regulates endosome-plasma membrane trafficking. Perturbations in endosome-plasma membrane trafficking that result from expression of the constitutively active ARF6 Q67L mutant vary with cell type, internalized protein, time of expression, and distribution of the actin cytoskeleton (Radhakrishna et al., 1996; Radhakrishna and Donaldson, 1997; Altschuler et al., 1999; Brown et al., 2001; Delaney et al., 2002; Palacios et al., 2002) . Long-term expression of the constitutively active ARF6 Q67L protein in PC12 cells resulted in the accumulation of a subset of plasma membrane constituents in an endosomal compartment. This likely resulted from both accelerated internalization as well as inhibited recycling of constituents back to the plasma membrane. Activated ARF6 likely enhances both clathrin-dependent and -independent pathways of inter- nalization in PC12 cells. Plasma membrane SNAP-25 is cointernalized with PIP 2 -containing, ARF6
Q67L -enriched membranes by a dynamin-independent pathway (unpublished data), but ARF6 Q67L -expressing cells also exhibit increased initial rates of transferrin uptake (unpublished data) presumed to be via clathrin-and dynamin-mediated endocytosis. ARF6 Q67L expression also accelerates the formation of synaptic vesicle-like endosomes in PC12 cells (Powelka and Buckley, 2001) that are formed by a clathrin-dependent pathway (Strasser et al., 1999) . These results indicate that multiple endocytic pathways are enhanced by expression of the constitutively active ARF6 Q67L in PC12 cells. ARF proteins directly activate PIP5K enzymes and regulate the synthesis of PIP 2 (Honda et al., 1999; Jones et al., 2000) . Plasma membrane PIP 2 is an essential cofactor for clathrin-dependent endocytosis (Barbieri et al., 2001; Cremona and DeCamilli, 2001; Galiano et al., 2002) , phagocytosis (Botelho et al., 2000) , pinocytosis (Schafer et al., 2000; Brown et al., 2001; Galiano et al., 2002) , and endosome motility (Rozelle et al., 2000; Schafer et al., 2000) . Thus, constitutive activation of PIP5K by ARF6 Q67L could enhance the internalization of plasma membrane constituents through multiple pathways (Radhakrishna and Donaldson, 1997; Brown et al., 2001; Claing et al., 2001; Palacios et al., 2002; Naslavsky et al., 2003) . However, ARF6-GTP cycling is essential for the trafficking of recycling endosomes back to the cell surface (Franco et al., 1999; Naslavsky et al., 2003) . Because this fails to occur in the GTPase-deficient ARF6 Q67L mutant, plasma membrane constituents are entrapped in an endosomal pool (Brown et al., 2001; Delaney et al., 2002; Palacios et al., 2002; Naslavsky et al., 2003) . In PC12 cells expressing ARF6 Q67L , an endosomal compartment containing ARF6 Q67L , PIP 2 , and PIP5K formed, which resulted in the depletion of these constituents from the plasma membrane.
Plasma membrane PIP 2 is essential for Ca 2ϩ -dependent DCV exocytosis at the plasma membrane (Hay et al., 1995; Holz et al., 2000) . That the depletion of PIP 2 from the plasma membrane in ARF6 Q67L -expressing PC12 cells was responsible for the inhibition of DCV exocytosis was established by demonstrating that expression or addition of PIP5K was capable of restoring regulated exocytosis in permeable cells incubated with MgATP. These results accounted for the absence of inhibition in permeable cell reconstitutions in which cytosol and MgATP were included, and strongly support the conclusion that plasma membrane PIP 2 is rate-limiting for DCV exocytosis in ARF6 Q67L -expressing cells. These results reinforce the conclusion that PIP 2 is essential for DCV exocytosis and indicate that ARF6 regulation of PIP5K plays a role in maintaining plasma membrane pools of PIP 2 required for exocytosis.
Regulation of PIP5K by ARF6 for Ca 2ϩ -dependent DCV exocytosis
The restoration of Ca 2ϩ -dependent DCV exocytosis in ARF6 Q67L -expressing permeable cells by PIP5K expression or addition explained the roles of cytosol and MgATP in the restoration, but not that of Ca 2ϩ . The role of Ca 2ϩ in the restoration may be mediated by PKC based on the effectiveness of a specific PKC pseudosubstrate inhibitor in blocking it. Although the involvement of PKC in Ca 2ϩ -dependent DCV exocytosis is well established (Nishizaki et al., 1992; Chen et al., 1999) , its precise role and the nature of PKC substrates involved in DCV exocytosis remain unknown. Park et al. (2001) reported that PKC contributes to the maintenance of cellular PIP 2 levels by regulating protein phosphatase-1, which catalyzes the dephosphorylation and activation of PIP5KI. The dephospho-PIP5KI␣ enzyme exhibits increased lipid kinase activity in vitro (Park et al., 2001 ), and we found that the cognate nonphosphorylatable S264A PIP5KI␥ enzyme was activated to synthesize plasma membrane PIP 2 and enhance Ca 2ϩ -dependent DCV exocytosis in PC12 cells. This result indicates that a nonphosphorylatable, activated PIP5KI␥ enzyme is a positive effector for regulated exocytosis, which is particularly significant because Wenk et al. (2001) found that PIP5KI␥ undergoes dephosphorylation in response to Ca 2ϩ influx into synaptosomes. Eberhard and Holz (1991) also reported that Ca 2ϩ influx increases PIP 2 synthesis in chromaffin cells. Together, these results indicate that PIP5K enzymes are Ca 2ϩ -dependent effectors that are activated to promote PIP 2 synthesis at the plasma membrane.
ARF6 at the plasma membrane likely mediates the membrane targeting and localization of the activated PIP5K enzymes (Honda et al., 1999) , and we found that wild-type PIP5K exhibited an increased association with ARF6 in response to Ca 2ϩ influx into PC12 cells. The Ca 2ϩ -dependent increase in ARF6 association may result from PIP5K dephosphorylation because the S264A mutant exhibited a strongly enhanced association with ARF6 that was not further increased by Ca 2ϩ influx. These results are consistent with a model (Fig. 9 ) in which Ca 2ϩ influx triggers the dephosphorylation of PIP5K, its increased association with ARF6, and its activation for plasma membrane PIP 2 synthesis.
Although the ATP-dependent priming of DCVs for Ca 2ϩ -dependent exocytosis is known to require PIP 2 synthesis (Hay et al., 1995) , our results provide the first indication that PIP 2 synthesis is regulated through an ARF6-dependent Ca 2ϩ -triggered mechanism. The reported Ca 2ϩ regulation of DCV priming (Bittner and Holz, 1992; Rettig and Neher, 2002) may in part be mediated by this ARF6-dependent pathway. The Ca 2ϩ -triggered stimulation of PIP5K activity, particularly of the type I␥ isoform that is enriched at synapses (Wenk et al., 2001) , would play an important role in enhancing Ca 2ϩ -triggered exocytosis and endocytosis. In nerve terminals, plasma membrane PIP 2 levels decrease immediately upon Ca 2ϩ influx (Micheva et al., 2001) , and the Ca 2ϩ -dependent recruitment and stimulation of PIP5K may be essential for the synthesis of additional PIP 2 needed to maintain rates of vesicle exocytosis and the endocytic retrieval of the vesicle membrane.
In conclusion, we present evidence that ARF6, through its regulation of PIP5K activity and PIP 2 synthesis, controls at least two types of peripheral membrane trafficking events in PC12 cells (Fig. 9) . Ca 2ϩ -dependent DCV exocytosis requires a plasma membrane pool of PIP 2 whose synthesis may be acutely regulated by Ca 2ϩ -dependent activation of ARF6-dependent PIP5K enzymes. ARF6-dependent PIP5K enzymes also regulate endosome-plasma membrane trafficking. An imbalance in the ARF6-regulated endosome recycling pathway can result in the depletion of plasma membrane constituents such as PIP 2 that are essential for DCV exocytosis.
Materials and methods
Constructs
The plasmid pXS-SR␣ containing COOH-terminal HA-tagged human ARF6 wild type, Q67L, and T27N were provided by J. Donaldson of the National Institutes of Health (NIH), Bethesda, MD. Constructs encoding COOH-terminal fusions of wild-type, Q67L, and T27N ARF6 proteins with EGFP were generated by PCR using the primers 5Ј-CGATAAGCTTATATC-CGACC-3Ј and 5Ј-GGATACTGCAGGGATTTG-3Ј. The PCR product was cleaved with HindIII and PstI and inserted into HindIII-PstI-digested pEGFP-N1 (CLONTECH Laboratories, Inc.). All constructs were confirmed by sequencing. Coding sequences from a pBS plasmid containing HAtagged murine full-length PIP5KI␥ provided by H. Ishihara (University of Tokyo, Tokyo, Japan) were excised with HindIII and VspI and subcloned into pcDNA 3.1 (Invitrogen). HA-tagged murine ⌬ 344-635 PIP5KI␥ was excised with HindIII and Alw441 and subcloned into pcDNA 3.1. The QuikChange ® Site-Directed Mutagenesis method (Stratagene) was used to generate the PIP5KI␥ (S264A) mutant using the sense primer 5Ј-CACGTA-CAAGCGCAGGGCCGCCAAGAAGGAGAAG-3Ј (mutation site underlined). The pCMVGH plasmid encoding hGH was provided by H. Herweijer (Mirus Corp., Madison, WI) and an expression vector encoding PLC ␦1 PH-GFP fusion protein provided by T. Balla (NIH).
Cell culture, transfection, and immunofluorescence
PC12 cells were cultured as described previously (Hay and Martin, 1992) . Cells were transfected with 50 g DNA in cytomix buffer (120 mM KCl, 0.15 mM CaCl 2 , 10 mM KH 2 PO 4 , 2 mM EGTA, 5 mM MgCl 2 , 2 mM MgATP, 5 mM glutathione, and 25 mM Hepes, pH 7.6) using an electroporator apparatus (Electroporator II; Invitrogen) set at 1,000 F and 330 V. 48 h after transfection, cells were washed with PBS, fixed with 4% formaldehyde (wt/vol), permeabilized with PBS containing 0.3% Triton X-100 or 0.2% saponin, and blocked in 10% FBS in PBS before antibody incubations. For PIP 2 localization in intact cells using anti-PIP 2 antibody, we used methods described previously (Laux et al., 2000) . For PIP 2 localization in permeable PC12 cells, the permeable cells were tethered to glutaraldehyde-activated, poly-L-lysine-coated glass coverslips (Wiedman et al., 1993) . Antibodies used were polyclonal ARF6 (J. Donaldson and V. Klenchin; University of Wisconsin, Madison, WI); monoclonal and polyclonal HA (BAbCO); monoclonal FLAG M2 (Sigma-Aldrich); monoclonal SNAP-25 (Sternberger); monoclonal TGN38 (K. Howell, University of Colorado, Denver, Co); polyclonal mannosidase II (K. Moremen, University of Georgia, Athens, GA); monoclonal Rab11 (Zymed Laboratories); monoclonal PIP 2 (K. Fukami, University of Tokyo); and monoclonal chromogranin B (W. Huttner, Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany). For transferrin uptake, transfected cells were incubated in medium containing 50 g/ml Texas red-conjugated transferrin (Molecular Probes, Inc.) for 30 min at 37ЊC, washed in PBS, and fixed. Images were obtained on an laser-scanning confocal microscope (MRC-600; Bio-Rad Laboratories) with a 63ϫ oil immersion objective. Quantitation of fluorescence was conducted with MetaMorph ® software (Universal Imaging Corp.) or SCION Image software (SCION Corp.).
Preparation of permeable PC12 cells and hGH secretion assays
hGH release experiments were performed 48 h after transfection. Adherent PC12 cells were incubated in medium containing 5 g/ml BFA (Epicentre) for 30 min at 37ЊC to inhibit constitutive hGH secretion without affecting Ca 2ϩ -dependent exocytosis. Cells were washed with Locke's solution (15 mM Hepes, pH 7.4, 145 mM NaCl, 5.6 mM KCl, 2.2 mM CaCl 2 , 5.6 mM glucose, 0.5 mM ascorbic acid, and 0.1% BSA) and incubated for 20 min with calcium-free Locke's solution or with elevated K ϩ solution (Locke's containing 59 mM KCl and 85 mM NaCl). Cell permeabilization and secretion assays were performed as described previously (Hay and Martin, 1992; Zhang et al., 2002) in KGlu buffer (50 mM Hepes, pH 7.2, 105 mM potassium glutamate, 20 mM potassium acetate, and 2 mM EGTA) with 0.1% BSA at 30ЊC. Single-stage assays contained 2 mM MgATP, 0.7 mg/ml rat brain cytosol, and 10 M free Ca 2ϩ . Two-stage assays used sequential incubations with MgATP plus cytosol and with Ca 2ϩ plus cytosol with intervening washes. hGH secreted into medium or low speed supernatants and in 0.1% SDS-lysed cells was measured by radioimmunoassay (Nichols Institute Diagnostics).
Immunoprecipitation assays
After transfection, cells were washed and incubated for 5 min with Locke's or elevated K ϩ buffer before harvesting in lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 or NP-40, 50 mM NaF, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, and Boehringer complete protease inhibitor cocktail). Lysates were sedimented and supernatants were adsorbed with protein G-Sepharose beads before conducting 3-16-h incubations with HA tag mAbs immobilized on protein G-Sepharose beads. Beads were washed five times with lysis buffer and eluted in sample buffer containing 0.2 M DTT for analysis by immunoblotting with ARF6 or HA antibodies.
